Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPO-HYPER II
2024-520231-33-00Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of vericiguat, tadalafil, eplerenone and citrulline in hypertension (HTN) (2 arms), sponsored by Karolinska University Hospital. Primary endpoint: Change in 24-hour ambulatory systolic blood pressure. Planned start Jul 2025; status: authorised.
02
Drugs
vericiguattadalafileplerenonecitrulline
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2024-520231-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520231-33-00.